Glaxosmithkline, LLC

Glaxosmithkline, LLC, a foreign-owned, for-profit pharmaceutical manufacturer headquartered in Durham, North Carolina, operates as a prime contractor supplying vaccines, antivirals, adjuvants, and related pharmaceutical products to federal agencies on a full-and-open basis. The vendor competes without SBA set-aside designations and holds no special certifications; it operates exclusively as a prime contractor with negligible sub-award footprint (less than 1% of recent activity). Primary NAICS classification is 325412 (Pharmaceutical Preparation Manufacturing); PSC coding centers on 6840 (Drugs and Biologicals).

Glaxosmithkline's federal capability portfolio centers on vaccine manufacturing, fill-finish operations, storage and stability services, and antiviral pharmaceuticals. Representative work includes a $1.465 billion IDV awarded by the CDC in April 2026 for pediatric and adult vaccines under the Vaccines for Children program; a $182.9 million single-award IDV from the Department of Veterans Affairs National Acquisition Center in August 2026 for Fluticasone/Salmeterol inhalers across VA, DoD, Bureau of Prisons, Indian Health Service, and Federal Health Care Center; a $94.4 million delivery order from the Office of the Assistant Secretary for Preparedness and Response (ASPR) in May 2024 for H5 pandemic preparedness medical countermeasures; and a $63.7 million definitive contract from ASPR in September 2025 for Relenza (zanamivir) Rotadisk antiviral supply through September 2030. Recent smaller awards include a $686 thousand delivery order from HHS Bureau of Administration in October 2026 for 2026-2027 flu vaccines and a $58 thousand CDC order from September 2026 for atovaquone and proguanil under Executive Order 14398 compliance.

Customer concentration is extreme and reflects the vendor's positioning as a critical national vaccine supplier. The CDC Pittsburgh office anchors 88 awards worth $19.72 billion in combined potential value; ASPR accounts for 56 awards valued at $7.57 billion. The Department of Veterans Affairs Veterans Health Administration Veterans Integrated Service Network 12 holds 29 awards with $11.83 billion combined potential value. Defense Logistics Agency Troop Support Medical places the highest volume by count—495 awards—but with only $402.9 million combined potential value, indicating small per-order magnitude. These five customer agencies account for 91% of all combined potential value across the vendor's federal footprint. Glaxosmithkline works with 144 distinct federal agencies overall, but procurement is heavily concentrated: the Department of Health and Human Services, Department of Veterans Affairs, and Defense Logistics Agency represent the preponderance of dollars and award activity.

Vehicle position reflects Glaxosmithkline's seat on multiple CDC and VA indefinite delivery contracts. The Pharmaceuticals and Drugs Federal Supply Schedule (FSS-61-IB) carries 248 task orders valued at $40.9 million combined potential. The vendor also holds multiple CDC IDVs for vaccines for children and vaccines for adults across fiscal years 2023 through 2026, with individual vehicle ceilings ranging from $13.9 million to $1.465 billion. A single-award VA National Acquisition Center IDV for influenza vaccines (36E79724D0005) anchors delivery orders from Bureau of Prisons facilities and Veterans Health Administration regional networks. Defense Logistics Agency IDVs (SPE2DP16D0009, SPE2DP18D0010, and related vehicles) carry smaller, high-volume zanamivir antiviral orders. These vehicles allow rapid task-order placement across federal customers without re-compete.

Activity has declined sharply in recent years. The vendor recorded 127 awards in 2022, 24 in 2023, 113 in 2024, 15 in 2025, and only 10 in 2026 year-to-date—a 92% drop from 2022 to 2026 baseline. Ten awards with combined potential value of $136.1 million reach ultimate completion within the next twenty-four months, creating significant recompete exposure. CDC and ASPR IDVs dominate this cliff: contracts for pandemic preparedness, vaccine adjuvant fill-finish and storage, pediatric and adult vaccine supply, and Fluticasone/Salmeterol inhaler supply all face expiration or option-exercise decisions in the 2026–2027 window. Loss of CDC vaccine vehicle renewal would eliminate approximately $19.7 billion in potential value.

Glaxosmithkline operates exclusively as a prime contractor; the vendor's sub-award footprint is negligible (one grant sub-award to Wisconsin Department of Health Services for SCHIP vaccine purchase represents the entire 0.06% sub-award activity). The vendor subcontracts minimally and carries no material sub-relationships with other federal primes. Federal grant work is absent; all activity flows through federal supply and delivery contracts managed by CDC, VA, ASPR, and DLA. The vendor's capability and market position rest entirely on its ability to serve as a direct pharmaceutical manufacturer and supplier to civilian health agencies and defense logistics.